Wedbush Maintains Outperform on Travere Therapeutics, Raises Price Target to $75

Benzinga · 2d ago
Wedbush analyst Laura Chico maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $61 to $75.